Regeneron Pharmaceuticals (REGN): How Dupixent’s Profit Economics Are Recasting the Company’s Next Growth Chapter!

Regeneron’s first-quarter results reinforce the company’s transition into a broader, scale-driven growth platform increasingly powered by Dupixent economics, oncology expansion, and pipeline diversification. Revenue rose 19% year over year to $3.6 billion, while non-GAAP EPS increased 15% despite elevated R&D investment supporting more than 40 clinical programs, highlighting strong underlying operating leverage. Dupixent remains the central earnings engine, with global sales increasing 31% to nearly $5 billion and Regeneron’s profit share surging 42% year over year. Importantly, the pending repayment of the Sanofi development balance by the end of Q2 is expected to materially increase collaboration profit contribution beginning in the second half, creating a meaningful earnings inflection. The ophthalmology franchise continues its transition toward EYLEA HD, which grew 52% year over year and now represents roughly half of U.S. retina sales, partially offsetting biosimilar pressure on legacy EYLEA. Beyond ophthalmology, oncology momentum is accelerating as Libtayo sales jumped 54%, while the complement and cardiometabolic pipelines introduce additional long-duration optionality through emerging programs in myasthenia gravis, obesity, and lipid management. Although temporary manufacturing disruptions and policy-related pricing uncertainty remain near-term headwinds, Regeneron’s strong balance sheet, rising free cash flow, and expanding portfolio breadth increasingly support a more diversified and durable earnings framework. Can Regeneron successfully transform Dupixent’s accelerating profit economics and its expanding late-stage pipeline into a sustained multi-engine growth model capable of offsetting future EYLEA erosion and redefining long-term valuation upside?